CRISPR Therapeutics AG (CRSP) Balance Sheet

As of 2026-06-30 (10-Q), CRISPR Therapeutics AG (CRSP) reported total assets of $2.7B, total liabilities of $904.2M and shareholders' equity of $1.7B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $291.3M. Long-term debt: $586.2M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CRSPCRISPR Therapeutics AGFollow CRSP — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 4.8B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Line	FY2016 Dec 16	FY2017 Dec 17	FY2018 Dec 18	FY2019 Dec 19	FY2020 Dec 20	FY2021 Dec 21	FY2022 Dec 22	FY2023 Dec 23	FY2024 Dec 24	FY2025 Dec 25	Latest Jun 26
Cash and equivalents	0.32	0.24	0.46	0.94	1.17	0.92	0.21	0.39	0.30	0.35	0.29
Short-term investments	—	—	—	0.00	0.52	1.46	1.60	1.30	1.61	1.63	2.07
Receivables	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.03	0.00	—
Current assets	0.32	0.25	0.47	0.99	1.72	2.42	1.85	1.91	1.94	1.99	2.37
Total assets	0.34	0.27	0.49	1.07	1.83	2.75	2.24	2.23	2.24	2.27	2.65
Current liabilities	0.02	0.01	0.03	0.06	0.09	0.12	0.12	0.11	0.09	0.15	0.13
Long-term debt	—	—	—	—	—	—	—	—	—	0.00	0.59
Total liabilities	0.11	0.08	0.10	0.13	0.16	0.35	0.37	0.35	0.31	0.34	0.90
Shareholders' equity	0.23	0.19	0.39	0.94	1.66	2.40	1.88	1.88	1.93	1.92	1.75

USD billions · SEC XBRL

CRISPR Therapeutics AG — questions

How much cash does CRISPR Therapeutics AG have?: $291.3M in cash and cash equivalents as of 2026-06-30.
How much debt does CRISPR Therapeutics AG have?: $586.2M of long-term debt as of 2026-06-30.
What are CRISPR Therapeutics AG's total assets?: $2.7B as of 2026-06-30.
What is CRISPR Therapeutics AG's shareholders' equity?: $1.7B as of 2026-06-30.

Every figure on this page comes from CRISPR Therapeutics AG's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.